En Es
Categories

Industry News

Seegene Develops World’s First Multiplex MDx Assays with AI System

By Labmedica International staff writers
09 Jan 2018

Image: Seegene has developed the world’s first molecular diagnostics assays using an artificial intelligence-based automated assay development system (Photo courtesy of Seegene).Seegene Inc. (Seoul, South Korea), a developer of multiplex PCR technologies, successfully developed molecular diagnostics (MDx) assays in just four days using an artificial intelligence- (AI) based automated assay development system. These assays are high multiplex real-time PCR reagents developed completely by AI and are meant for the simultaneous detection of eight different DNA targets for each of meningitis and sexually transmitted infections.

The Seegene Digitalized Development System (SG-DDS) automates real-time PCR assay development by utilizing big data of causative agents for diseases, Seegene's novel algorithms, and in silico oligonucleotide design with virtual experiments. This significantly reduces the time and labor required for R&D and simplifies the complicated real time PCR assay development processes, thereby allowing even non-professionals to easily develop multiplex MDx assays according to their requirement.

"The performance (sensitivity and specificity) of the assays developed by AI are equivalent to or even better than that of those manually developed," said a spokesperson from Seegene. "Only four days were sufficient by the AI system to successfully develop two 8-plex assays, while more than a year was required by a team of experienced professionals."

"We have already witnessed AI surpassing human intelligence in developing medical devices. Therefore, all molecular diagnostic assays will be developed by AI instead of professional researchers," added Dr. Jong-Yoon Chun, CEO and Founder of Seegene. "SG-DDS is now the most economical solution to MDx assay development as it saves time and labor, and will ultimately drive down the cost of molecular diagnostic tests, one of the biggest obstacles in MDx market. SG-DDS will lead to standardization of MDx system and promote tailor-made medical treatment."



E-mail Print
FaceBook Twitter Google+ Linked in

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology. The company’s products detect multi-pathogens with high sensitivity, specificity and reproducibility, resulting in saving of time, labor and cost.
More info

More articles about Seegene

19 Apr 2018
Seegene Unveils Combination Test at ECCMID 2018
Seegene Inc., a developer of multiplex PCR technologies, introduced a combination test at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) held in Madrid, Spain, from April 21 to 24, 2018. The combination test is a high-efficiency solution that diagnoses various causes of diseases with multiplex molecular diagnosis assays. Seegene also showcased its molecular diagnostic system SGSTAR (Seegene Sameday Test and Report), which allows order-to-report on the same day and enables the running of the combination test.
Read More
28 Sep 2017
Seegene Partners with Hamilton to Develop Random Access System
Seegene, a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx), has signed a Memorandum of Understanding (MoU) with Hamilton Company, which designs and manufactures precision measurement devices, automated liquid handling workstations, and sample management systems, to develop the Seegene Random Access System.
Read More
29 May 2017
Seegene Collaborates with Thermo to Enter US Market
Seegene Inc., a developer of multiplex molecular diagnostics technologies and assays, has entered into a collaboration with Thermo Fisher Scientific, in which Seegene will file for U.S. Food and Drug Administration (FDA) clearance of its Allplex diagnostic assay portfolio at the same time that Thermo Fisher files for FDA clearance to run Seegene's assays on Thermo Fisher's QuantStudio 5 Real-Time PCR System (PCR System).
Read More

Additional news

08 Jan 2019
New AI Technology Pinpoints Negative Symptoms in Cancer Patients
Researchers from the University of Surrey and the University of California have developed a new artificial intelligence (AI) tool, which can predict symptoms and their severity throughout the course of a cancer patient's treatment.
Read More
08 Jan 2019
Luminex Acquires MilliporeSigma Flow Cytometry Portfolio
Luminex Corporation has completed its previously announced acquisition of MilliporeSigma's flow cytometry portfolio.
Read More
31 Dec 2018
Deep Learning Technique Could Reveal Transparent Features in Medical Images
Engineers at the Massachusetts Institute of Technology have developed a deep learning technique that can reveal images of transparent features or objects that are nearly impossible to decipher in almost total darkness.
Read More
31 Dec 2018
Next-Gen Products Driving Global POC Molecular Diagnostics Market
The global point of care (POC) molecular diagnostics market is expected to grow at a CAGR of close to 14% during the period 2019-2023, driven mainly by the growing number of M&As and collaborations, and rising focus on next-generation products.
Read More
31 Dec 2018
Increased Breast Cancer Driving Global Digital Breast Tomosynthesis Market
The global digital breast tomosynthesis market is expected to grow at a CAGR of around 13% for the period 2019-2023, driven by the increasing incidence of breast cancer, growing popularity of digital breast tomosynthesis and consistent launch of new products.
Read More
31 Dec 2018
Global Urinalysis Market to Reach USD 1.5 Billion by 2024
The global urinalysis market is expected to grow at a steady CAGR of 5.40% over the 2016-2024 period to reach a value of USD 1.5 billion by the end of 2024, propelled mainly by the rising incidence of diabetes and urinal infections, globally.
Read More
31 Dec 2018
Bruker Completes Acquisition of Alicona Imaging
Bruker Corporation has completed its previously announced acquisition of Alicona Imaging GmbH, a provider of optical-based metrology products.
Read More
25 Dec 2018
New AI-Based Solutions Create Possibility for Early Cancer Screening
Two new Artificial Intelligence- (AI) based products released at this year’s Radiological Society of North America (RSNA) annual meeting in Chicago, USA, could create possibility for large-scale early cancer screening globally.
Read More
25 Dec 2018
Network-Based AI Engine Performs Airway Segmentation from CT Images
A new 2.5D convolutional neural network (CNN)-based artificial intelligence (AI) engine enables accurate airway segmentation from computed tomography (CT) images without any human interaction.
Read More
Copyright © 2000-2019 TradeMed.com. All rights reserved. | Terms And Conditions